Get started
Live feed
PRReleasevia Quantisnow
Johnson & Johnson logo

Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026

ByQuantisnow··Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Historical context for JNJ

Across the 24 sessions after earlier JNJ headlines, the stock closed higher 11 times and lower 13 times, with a median move of 0.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

JNJ close-to-close change in the session after earlier headlines
SessionEarlier headlineJNJSPY
Oct 21, 2026Johnson & Johnson downgraded by Erste Group-0.6%+0.5%
Oct 19, 2026Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula-0.7%+0.4%
Oct 13, 2026Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026and 3 other headlines that session-5.7%-0.0%
Oct 9, 2026New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis+1.9%+0.6%
Oct 2, 2026Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy-1.0%+0.7%
Oct 1, 2026New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause-2.3%+0.2%

Keep researching JNJ

Quantisnow market dataNYSE
Johnson & Johnson logo
JNJ
Johnson & Johnson
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Get push alerts for JNJ

Follow JNJ and get a push notification the moment its next story breaks.

Full JNJ profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JNJ (Johnson & Johnson) and more on Quantisnow.